Testing nerandomilast for children with lung scarring
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 2 and under 18 years old
- Have lung scarring (fibrosing ILD) confirmed by a special CT scan within the past year
- If age 6 or older, have a lung function test (FVC) that is at least 25% of predicted normal
- Show signs that the lung disease is getting worse, such as a drop in lung function, more scarring, or needing more oxygen
- Not have taken this drug (nerandomilast) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial tests whether combining two medications, nerandomilast and mycophenolate, helps people with different types of pulmonary fibrosis (lung scarring). It aims to see if this combination is safe and works well for various subtypes other than IPF.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Hear when a new Fibrosing Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.